Latest Director Resignation News

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

IGO Limited reports improved safety metrics and steady production despite operational headwinds, maintaining a strong balance sheet and positive cash flow.

Black Dragon Gold’s latest quarterly report highlights strong local backing for its Salave gold project in Spain, alongside a key director resignation and a stable cash position of CAD$882,000.

Sunshine Metals reports significant progress in North Queensland with standout gold intersections at Sybil and a $5 million placement led by Lion Selection. Board reshuffle aligns leadership with growth strategy.

Galileo Mining’s latest drilling at Norseman confirms significant palladium, platinum, and gold mineralisation over a 10km strike, underpinning plans for follow-up resource testing. The company remains well-capitalised to advance exploration.

Johns Lyng Group has officially been acquired by Sherwood BidCo, controlled by Pacific Equity Partners, with shareholders receiving $4.00 per share or equity in the new entity. The company will be delisted from the ASX on October 24, marking a new chapter under private ownership.

Equity Story Group has raised $650,000 through a strategic convertible loan led by new Non-Executive Chair Alex Brinkmeyer, signaling a pivot into property funds management. The company also announced significant board changes, including the appointment of David Nolan as Managing Director.

Platinum Asset Management has finalized its merger with L1 Capital, issuing over 1.65 billion new shares and announcing a rebrand to L1 Group Limited alongside significant board changes and share escrow arrangements.

Dalrymple Bay Infrastructure has appointed CEO Michael Riches as Managing Director, coinciding with the resignation of two non-executive directors following a significant shareholder sell-down.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Golden State Mining has raised $1.5 million through a strategic share placement to fund its gold exploration projects and potential acquisitions, alongside notable board changes signaling a new chapter for the company.

RooLife Group Ltd reported a sharp 51% revenue decline to $4.62 million and a 31% increase in net loss to $2.76 million for FY2025, as it pivots towards higher-margin sectors including renewable energy and global social commerce.